Geoffrey Duyk, Grove Biopharma CEO, on Polymer Breakthroughs, Intractable Targets & Biotech's Future
Synopsis:
Host Rahul Chaturvedi sits down with Geoffrey Duyk, Chief Executive Officer of Grove Biopharma, for a wide-ranging conversation on navigating today’s biotech macro headwinds and building companies that can translate breakthrough science into real patient impact. Dr. Duyk traces his journey from Harvard/Millennium/Exelixis operator to TPG investor and back to company creation, explaining how board dynamics, capital cycles, and policy shifts shape execution.
They dig into why this cycle feels uniquely tough—patent cliffs, reimbursement uncertainty, NIH pressures—and who funds innovation in the meantime. Duyk outlines root causes of R&D inefficiency (misaligned capital vs. 20-year timelines, shaky preclinical predictability, costly trials, underused real-world data) and makes the case for rebuilding public trust and STEM education.
Then, a deep dive on Grove Biopharma: precision polymer science that creates antibody-like, fully synthetic, cell-permeable protein mimetics to tackle historically “intractable” intracellular protein–protein interactions. Duyk shares design principles, why modular/orthogonal chemistry matters, predictable pharmacology, and lessons from fundraising and board management—plus why he’s helping grow a Chicago-centered biotech ecosystem.
Biography:
Geoffrey M. Duyk, M.D., Ph.D. is the Chief Executive Officer of Grove Biopharma.
Dr. Duyk has spent 30 years in the biotechnology industry as an entrepreneur, executive, and investor. Most recently, he was the Managing Partner at Circularis Partners, an investment firm he co-founded, focused on advancing the circular economy and promoting sustainability. Prior to that, Dr. Duyk was Managing Director and Partner at TPG Alternative & Renewable Technologies (ART)/TPG Biotechnology.
Before joining TPG, Dr. Duyk served as a board member and President of R&D at Exelixis and was one of the founding scientific staff members at Millennium Pharmaceuticals, where he served as Vice President of Genomics. Earlier in his career, Dr. Duyk was an Assistant Professor in the Department of Genetics at Harvard Medical School (HMS) and an Assistant Investigator at the Howard Hughes Medical Institute (HHMI). While at HMS, he served as a co–principal investigator in the Cooperative Human Linkage Center, which was funded by the National Institutes of Health (NIH).
Dr. Duyk is a trustee of Case Western Reserve University, where he serves on the executive committee. He previously served on the Board of Trustees of Wesleyan University and the Board of Directors of the Moffitt Cancer Center. He currently serves on the IR&E (Institutional Research and Evaluation) Committee at Moffitt, a key component of its External Advisory Committee (EAC). He was also a member of the Board of Directors of the American Society of Human Genetics (ASHG), and served as its treasurer. He is a member of the Life Sciences Advisory Board at Innovatus Capital Partners and the Scientific Advisory Board (SAB) for Lawrence Berkeley National Laboratory (DOE). Dr. Duyk previously served on the board of the Jackson Laboratory and on numerous NIH advisory committees. He is currently a Senior Advisor at Qiming Venture Partners (USA) and serves on the boards of Enno DC, Oobli, and Melanyze
Dr. Duyk earned both his M.D. and Ph.D. from Case Western Reserve University and completed his medical and fellowship training at the University of California, San Francisco (UCSF). While at UCSF, he was a Lucille P. Markey Fellow and an HHMI postdoctoral fellow. He is a fellow of the American Association for the Advancement of Science.
Sverige